Optimal control analysis of a leukemia model under imatinib treatment
نویسندگان
چکیده
The paper is devoted to the study of a mathematical model of drug therapy for Chronic Myelogenous Leukemia (CML). The disease dynamics are given by a couple of delay differential equations that describe the interaction between a stem-like population of CML cells and a more mature, differentiated one, without self-renewal properties. A molecular targeted therapy, such as Imatinib, is considered. The objective is to minimize the size of the tumoral cells’ mass while minimizing the amount of drug (thus, minimizing both the adverse effects and the costs). The optimal control is calculated using a discretization scheme. The results are supported by numerical simulations.
منابع مشابه
Analysis of Expression Of SIRT1 Gene In Patients With Chronic Myeloid Leukemia Resistant To Imatinib Mesylate
Background: Chronic myeloid leukemia is a clonal myeloproliferative disease which is characterized by bcr/abl translocation. With the emergence of tyrosine kinase inhibitors such as imatinib mesylate, significant improvement has been made in treatment of this disease. However, drug resistance against this medicine is still an obstacle. SIRT1 is a gene with deacetylase activity which has been de...
متن کاملCoexistence of BCR-ABL1 Translocation and JAK2 V617F Mutation in a Patient with Chronic Myeloid Leukemia Under Long-term Treatment with Imatinib and Nilotinib: A Case Report
This report describes an 89-year-old woman diagnosed with Philadelphia positive Chronic Myeloid Leukemia in 2007 who was initially treated with 200 mg/day imatinib. The patient demonstrated complete molecular response (CMR) in two tests in 2015 and 2018. During treatment between 2007 and 2019, despite increased dosage of imatinib and switching her therapy to nilotinib, complete hematological r...
متن کاملGRUNWALD-LETNIKOV SCHEME FOR SYSTEM OF CHRONIC MYELOGENOUS LEUKEMIA FRACTIONAL DIFFERENTIAL EQUATIONS AND ITS OPTIMAL CONTROL OF DRUG TREATMENT
In this article, a mathematical model describing the growth orterminating myelogenous leukemia blood cancer's cells against naive T-celland eective T-cell population of body, presented by fractional dierentialequations. We use this model to analyze the stability of the dynamics, whichoccur in the local interaction of eector-immune cell and tumor cells. Wewill also investigate the optimal contro...
متن کاملThe long-term outcome and efficacy of PR1/BCR-ABL multipeptides vaccination in chronic myeloid leukemia: results of a 7-year longitudinal investigation
Background: Although Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), not all patients reach complete remission and a considerable proportion of the patients develop resistance to Imatinib. Material and Methods: In an attempt to increase the tail on the survival curve, we conducted a Phase I/II study of PR1/BCR-ABL multipeptides vaccination trial in CML patients wit...
متن کاملPregnancy Outcome of Two Patients with Chronic Myelogenous Leukemia Treated with Imatinib
Although chronic myelogenous leukemia in pregnancy is rare, its management and treatment is more difficult and complicated.Treatment of patients with chronic myelogenous leukemia includes bone marrow transplantation, however in less than 30% of patients the donor’s organ would be accepted. To this end, cytotoxic therapy is considered as an alternative therapeutic option. This option provides sa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Mathematics and Computers in Simulation
دوره 121 شماره
صفحات -
تاریخ انتشار 2016